Is American Express Company (AXP)’s Executive Selling Spree a Red Flag?

Page 1 of 2

On the heels of its lackluster earnings release, American Express Company (NYSE:AXP)‘ stock has hit five-year highs. And while investors and analysts celebrate the company’s forward-thinking business plans and momentum, company executives have been purging their shares. Here’s what investors need to know about how to view insider transactions going forward.

Between Jan. 21 and Jan. 29, executives from American Express sold 357,758 shares through direct sales and options exercises for a total cash-out of $21.2 million. While AmEx executives may have sold a lot of shares, it doesn’t necessarily mean that they are trying to get out before the bottom falls out from under them. According to a company spokesperson, there are limited windows during the year when executives can buy or sell shares, such as after the release of earnings.

American Express Company (NYSE:AXP)Like most companies, American Express has rules for executives, with minimum ownership requirements. After the sales occurred, the sellers still met all of the company requirements. In fact, AmEx was one of the financial companies with decent insider ownership as of year end 2011.

Company % Insider Ownership*
Capital One Financial Corp. (NYSE:COF) 2.91%
American Express 1.31%
JPMorgan Chase & Co. (NYSE:JPM) 0.81%
Citigroup Inc. (NYSE:C) 0.19%
Bank of America Corp (NYSE:BAC) 0.07%

Source: Companies 2012 proxy statements and Yahoo! Finance; all percentages refer to ownership at year-end 2011.

All of the companies listed above had insider transactions throughout January, according to Yahoo! Finance, so the share sales from AmEx executives is not a one-off, troublesome event. It’s not uncommon for insiders to buy and sell shares throughout the year, so investors need to keep the transactions in perspective.

Money, money, money…
Here at the Fool, insider ownership is one of the key statistics used to evaluate a company. But while it’s an important factor, it’s not everything. Investors should look at insider ownership — and so, by degree — insider selling, with an eye toward context.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!